Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6899318 | 0.98 | CYP1A2 (0.96) | CYP1A2CYP3A4CYP2D6PRMT1POLB | |
| SCHEMBL12879664 | 0.81 | CYP2D6 (0.68) | CYP1A2CYP3A4CYP2D6PRMT1POLB | |
| SCHEMBL11188983 | 0.79 | CYP2D6 (0.66) | CYP1A2CYP3A4CYP2D6PRMT1POLB | |
| SCHEMBL5680420 | 0.78 | CYP2D6 (0.63) | CYP1A2CYP3A4CYP2D6PRMT1POLB | |
| SCHEMBL6578267 | 0.77 | CYP3A4 (0.62) | CYP1A2CYP3A4CYP2D6PRMT1TAAR1 | |
| Carbocysteine SCHEMBL11552772 | 0.77 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2D6PRMT1 | |
| SCHEMBL18272090 | 0.76 | CYP2D6 (0.61) | CYP1A2CYP3A4CYP2D6PRMT1POLB | |
| SCHEMBL7796812 | 0.76 | CYP2D6 (0.61) | CYP1A2CYP3A4CYP2D6PRMT1POLB | |
| SCHEMBL5193497 | 0.76 | CYP3A4 (0.61) | CYP1A2CYP3A4CYP2D6PRMT1TAAR1 | |
| SCHEMBL6431176 | 0.75 | CYP3A4 (0.59) | CYP1A2CYP3A4CYP2D6PRMT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4035492-A | Oral treatment of seborrhea with cysteamine derivatives | L'OREAL (FR) | 1977-07-12 | — | — | US | claimed |
| US-4002671-A | REDUCE SEBUM SECRETION ON SCALP OR SKIN | SOCIETE ANONYME DITE: L'OREAL (FR) | 1977-01-11 | — | — | US | claimed |
| US-20230404947-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11771665-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-20220347126-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11406607-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11369568-B2 | Microparticles comprising a sulphur-containing compound | NOVABIOTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021203136-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-2308839-A1 | Fused heterocyclic compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-7297820-B2 | Stilbene derivatives and their use for binding and imaging amyloid plaques | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-11-20 | — | — | US | disclosed |
| US-7250525-B2 | Stilbene derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-07-31 | — | — | US | disclosed |
| US-5312904-A | Body imaging agents | AMERSHAM INTERNATIONAL PLC (GB) | 1994-05-17 | — | — | US | disclosed |
| EP-0386873-B1 | CATIONIC COMPLEXES OF TECHNETIUM 99M, AND LIGANDS THEREFOR | AMERSHAM INTERNATIONAL plc (GB) | 1993-09-15 | — | — | EP | disclosed |
| EP-0386873-A1 | Cationic complexes of technetium 99m, and ligands therefor | AMERSHAM INTERNATIONAL plc (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4002671-A | REDUCE SEBUM SECRETION ON SCALP OR SKIN | SOCIETE ANONYME DITE: L'OREAL (FR) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | MAVS, HAVCR2, IRF3 | CYP1A2 4058/4885CYP3A4 3476/4885CYP2D6 4331/4885 |
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | CYP1A2 730/4885CYP3A4 336/4885CYP2D6 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.